Cargando…
Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor
Liver cancer is the fastest growing cause of cancer deaths in the United States due to its aggressiveness and lack of effective therapies. The current preclinical study examines valeric acid (pentanoic acid [C(5)H(10)O(2)]), one of the main compounds of valerian root extract, for its therapeutic use...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520432/ https://www.ncbi.nlm.nih.gov/pubmed/33024815 http://dx.doi.org/10.1016/j.omto.2020.08.017 |
_version_ | 1783587785134833664 |
---|---|
author | Han, Rui Nusbaum, Olivia Chen, Xinyi Zhu, Yong |
author_facet | Han, Rui Nusbaum, Olivia Chen, Xinyi Zhu, Yong |
author_sort | Han, Rui |
collection | PubMed |
description | Liver cancer is the fastest growing cause of cancer deaths in the United States due to its aggressiveness and lack of effective therapies. The current preclinical study examines valeric acid (pentanoic acid [C(5)H(10)O(2)]), one of the main compounds of valerian root extract, for its therapeutic use in liver cancer treatment. Anticancer efficacy of valeric acid was tested in a series of in vitro assays and orthotopic xenograft mouse models. The molecular target of valeric acid was also predicted, followed by functional confirmation. Valeric acid has a broad spectrum of anticancer activity with specifically high cytotoxicity for liver cancer in cell proliferation, colony formation, wound healing, cell invasion, and 3D spheroid formation assays. Mouse models further demonstrate that systematic administration of lipid-based nanoparticle-encapsulated valeric acid significantly reduces the tumor burden and improves survival rate. Histone deacetylase (HDAC)-inhibiting functions of valeric acid are also revealed by a structural target prediction tool and HDAC activity assay. Further transcriptional profiling and network analyses illustrate that valeric acid affects several cancer-related pathways that may induce apoptosis. In summary, we demonstrate for the first time that valeric acid suppresses liver cancer development by acting as a potential novel HDAC inhibitor, which warrants further investigation on its therapeutic implications. |
format | Online Article Text |
id | pubmed-7520432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-75204322020-10-05 Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor Han, Rui Nusbaum, Olivia Chen, Xinyi Zhu, Yong Mol Ther Oncolytics Original Article Liver cancer is the fastest growing cause of cancer deaths in the United States due to its aggressiveness and lack of effective therapies. The current preclinical study examines valeric acid (pentanoic acid [C(5)H(10)O(2)]), one of the main compounds of valerian root extract, for its therapeutic use in liver cancer treatment. Anticancer efficacy of valeric acid was tested in a series of in vitro assays and orthotopic xenograft mouse models. The molecular target of valeric acid was also predicted, followed by functional confirmation. Valeric acid has a broad spectrum of anticancer activity with specifically high cytotoxicity for liver cancer in cell proliferation, colony formation, wound healing, cell invasion, and 3D spheroid formation assays. Mouse models further demonstrate that systematic administration of lipid-based nanoparticle-encapsulated valeric acid significantly reduces the tumor burden and improves survival rate. Histone deacetylase (HDAC)-inhibiting functions of valeric acid are also revealed by a structural target prediction tool and HDAC activity assay. Further transcriptional profiling and network analyses illustrate that valeric acid affects several cancer-related pathways that may induce apoptosis. In summary, we demonstrate for the first time that valeric acid suppresses liver cancer development by acting as a potential novel HDAC inhibitor, which warrants further investigation on its therapeutic implications. American Society of Gene & Cell Therapy 2020-08-29 /pmc/articles/PMC7520432/ /pubmed/33024815 http://dx.doi.org/10.1016/j.omto.2020.08.017 Text en © 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Han, Rui Nusbaum, Olivia Chen, Xinyi Zhu, Yong Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title | Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title_full | Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title_fullStr | Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title_full_unstemmed | Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title_short | Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor |
title_sort | valeric acid suppresses liver cancer development by acting as a novel hdac inhibitor |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520432/ https://www.ncbi.nlm.nih.gov/pubmed/33024815 http://dx.doi.org/10.1016/j.omto.2020.08.017 |
work_keys_str_mv | AT hanrui valericacidsuppresseslivercancerdevelopmentbyactingasanovelhdacinhibitor AT nusbaumolivia valericacidsuppresseslivercancerdevelopmentbyactingasanovelhdacinhibitor AT chenxinyi valericacidsuppresseslivercancerdevelopmentbyactingasanovelhdacinhibitor AT zhuyong valericacidsuppresseslivercancerdevelopmentbyactingasanovelhdacinhibitor |